Category Archives: Jim’s Corner

On February 4th, BIO hosted a media briefing on how efforts to restrict gene patenting and licensing would threaten advances in public health and harm the national economy. Participants included: BIO President & CEO Jim Greenwood; Senator Birch Bayh, co-author of the Bayh-Dole Act; Brian Stanton, Ph.D., Task Force Member on Intellectual Property and Access to Genetic Testing; Jim Davis, Ph.D., J.D., General Counsel of Human Genome Sciences, Inc.; Jon Soderstrom, Ph.D., Managing Director of Read More >

When we look at the challenges affecting our world today, many come to mind – energy demand, food security and climate change, just to name a few. Biotechnology provides tools to meet all of these challenges. The sustainable farming practices afforded to today’s modern farmers allow us to produce more food, fuel and fiber on less land with less environmental impact. These technologies – and the policies and infrastructures needed to realize their benefit – Read More >

Last summer, BIO joined with former Vermont Governor Howard Dean to advocate for biosimilar legislation that protects patient safety and promotes necessary incentives for continued innovation of biologics. The Governor, a trained physician, is a passionate supporter of the value of biotech products in treating disease and reducing healthcare costs. To further familiarize him with the diversity of our member companies, I accompanied Governor Dean for a two-day tour of California biotech companies earlier this Read More >

Biotechnology is a global enterprise.  The United States continues to play the dominant role but European and Asian nations are continually expanding their capabilities. In preparation for BIO’s first ever partnering meeting in India in September 2010, I am travelling the subcontinent to promote the event and to assess the country’s biotech capabilities and needs. On November 4th in Mumbai, I visited Reliance Life Sciences which represents a huge investment in biotech from one of Read More >